PALATINE, Ill., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2017.
The Company reported a net loss of $2.15 million or $0.18 per diluted share for quarter ended June 30, 2017 compared to a net loss of $3.3 million or $0.28 per diluted share for the same period in 2016. For the six months ended June 30, 2017 the Company reported net loss of $1.7 million or $0.15 per diluted share, compared to net loss of $6.6 million or $0.56 per diluted share for the same period in 2016.
